Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533651 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL7001136 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL1939902 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL25253582 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL12168188 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL2712060 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21898011 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL27035866 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL11750711 | 0.84 | ENPP2 (0.78) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL485156 | 0.83 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | SMN1; SMN2 2573/4885NPC1 1598/4885RAB9A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.